ArticleThe Journal of allergy and clinical immunology2011

Successful canakinumab treatment identifies IL-1β as a pivotal mediator in Schnitzler syndrome.

Heleen D de Koning et al.PubMed ↗Publisher ↗

No numbers read from the abstract.